---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-106669"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:10:38.251328+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics appoints Kathryn Penkus Corzo to Board; CEO granted 250,000 options

## Summary
- Kathryn Penkus Corzo appointed to Board effective Nov 1, 2025; she brings 30+ years of biopharma leadership.
- Corzo currently President/COO of bit.bio; previously Head of Oncology Cell Therapy at Takeda Ventures.
- Corzo received 147,611 stock options as non-employee director compensation, vesting over 36 months.
- CEO Juan Vera granted 250,000 stock options, vesting annually over 4 years under the 2020 Plan.

## SEC filing metadata
- accession: 0001104659-25-106669
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925106669/0001104659-25-106669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925106669/tm2530129d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-106669
- JSON: https://secwatch.observer/filing/0001104659-25-106669.json
- Plain text: https://secwatch.observer/filing/0001104659-25-106669.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.